A personalized approach to cancer treatment: how biomarkers can help.
Material type: TextSeries: Staff Publications ; Staff Publications- Crown, JohnPublication details: 2008.Subject(s):- BACKGROUND: The present approach to cancer treatment is often referred to as inappropriate therapy and treatment-related toxicity. In contrast, personalized treatment has the potential to increase efficacy and decrease toxicity. CONTENT: We reviewed the literature relevant to prognostic, predictive, and toxicity-related markers in cancer, with particular attention to systematic reviews, prospective randomized trials, and guidelines issued by expert panels. To achieve personalized treatment for cancer, we need markers for determining prognosis, predicting response to therapy, and predicting severe toxicity related to treatment. Among the best-validated prognostic markers currently available are serum concentrations of alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and lactate dehydrogenase (LDH) for patients with nonseminoma germ cell tumors and tissue concentrations of both urokinase plasminogen activator and plasminogen activator inhibitor 1 (PAI-1) for breast cancer patients. Clinically useful therapy predictive markers are estrogen and progesterone receptors to select patients with breast cancer for treatment with endocrine therapy and human epidermal growth factor receptor 2 (HER-2) to select breast cancer patients for treatment with trastuzumab (Herceptin). Markers available for identifying drug-induced adverse reactions include thiopurine methyltransferase (TPMT) to predict toxicity from thiopurines in the treatment of acute lymphoblastic leukemia and uridine diphosphate glucuronyltransferase to predict toxicity from irinotecan in the treatment of colorectal cancer
- PUBLICATIONS ARCHIVE CROW
Item type | Current library | Home library | Shelving location | Call number | Status | Date due | Barcode | Item holds | |
---|---|---|---|---|---|---|---|---|---|
2 Week Loan | St. Luke’s Radiation Oncology Network Dublin | St. Luke’s Radiation Oncology Network Dublin | AR | PUBLICATIONS ARCHIVE CARN (Browse shelf(Opens below)) | Available | 39015000019813 |
Total holds: 0
The print version of this article is held in the Oncology Resource Centre (Box 1).
There are no comments on this title.
Log in to your account to post a comment.